Non-interventional Study on Oral Contraception Not Containing Ethinylestradiol (EE) to Assess Continuation Rates and Satisfaction

• Time to event for discontinuation due to reasons other than bleeding irregularities [ Time Frame: Month 3-5 ] [ Designated as safety issue: No ]
• Time to event for discontinuation due to reasons other than bleeding irregularities [ Time Frame: Month 6-12 ] [ Designated as safety issue: No ]
• Number of intracyclic bleeding [ Time Frame: Month 3-5 ] [ Designated as safety issue: No ]
• Number of intracyclic bleeding [ Time Frame: Month 6-12 ] [ Designated as safety issue: No ]
• Number of heavy and/or prolonged bleeding [ Time Frame: Month 3-5 ] [ Designated as safety issue: No ]
• Number of heavy and/or prolonged bleeding [ Time Frame: Month 6-12 ] [ Designated as safety issue: No ]
• Number of unintended pregnancies [ Time Frame: Month 3-5 ] [ Designated as safety issue: No ]
• Number of unintended pregnancies [ Time Frame: Month 6-12 ] [ Designated as safety issue: No ]
• Discontinuation rate for the following reasons: Occasional absent or persistent absent withdrawal bleeding , intracyclic bleeding, heavy and/or prolonged bleeding, other medical reasons, non-medical reasons [ Time Frame: Month 3-5 ] [ Designated as safety issue: No ]
• Discontinuation rate for the following reasons: Occasional absent or persistent absent withdrawal bleeding , intracyclic bleeding, heavy and/or prolonged bleeding, other medical reasons, non-medical reasons [ Time Frame: Month 6-12 ] [ Designated as safety issue: No ]
• Global assessment of well-being and satisfaction [ Time Frame: Month 3-5 ] [ Designated as safety issue: No ]
• Global assessment of well-being and satisfaction [ Time Frame: Month 6-12 ] [ Designated as safety issue: No ]
• Adverse events (AEs) at any time point, whether or not related to the therapy or reference therapy [ Time Frame: up to 12 Months ] [ Designated as safety issue: Yes ]

Prospective, non-interventional, multi-center study. Each subject will be followed for up to twelve months during the treatment with oral hormonal contraceptives(Qlaira ® or a Progestin Only Pill). For each subject demographic data and medical history will be documented at Visit 1: (Baseline). Bleeding profile, subjective assessment of study treatment (satisfaction and wellbeing) and adverse events including unintended pregnancies will be documented at Visit 2 (Month 3-5) and Visit 3 (Month 6-12). Data audit/monitoring will be done.

Women in gynecological practice

• Drug: EV/DNG (Qlaira, BAY86-5027)
  At the discretion of the attending physician
• Drug: Progestin Only Pills
  At the discretion of the attending physician

• Group 1
  Intervention: Drug: EV/DNG (Qlaira, BAY86-5027)
• Group 2
  Intervention: Drug: Progestin Only Pills

Inclusion Criteria:

• Women between 18-50 years
• Women who used ethinylestradiol containing oral contraceptives for at least the three preceding months before the study
• Women who decided to start Qlaira® or a Progestin Only Pill. The prescription of the hormonal contraceptive is made at the discretion of the attending physician and has to be documented

Exclusion Criteria:

• Contraindications and warnings of the respective Summary of Product Characteristics (Qlaira® or Progestin Only Pill)
• Women who are breast-feeding